Posted on by

Onco-Innovations Engages NSP to Advance Polymer and Drug Delivery Development for ONC010

June 23, 2026

NSP is pleased to support Onco-Innovations Limited in the continued development of ONC010, its lead nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor.

Under a services agreement announced by Onco-Innovations, NSP will provide polymer process development, analytical characterization, scale-up support, formulation optimization, and technology transfer services for Onco-Innovations’ proprietary PEO-PBCL polymer platform.

The program is focused on establishing a robust and reproducible polymer manufacturing process, strengthening analytical methods, and supporting process scale-up and future technology transfer. These activities are intended to help establish the technical and manufacturing foundation required as the ONC010 program progresses through further development.

The collaboration reflects NSP’s capabilities in functional polymer synthesis, polymer process development, analytical characterization, nanoparticle drug delivery, and scalable manufacturing.

NSP looks forward to applying its polymer science and drug delivery expertise to support the advancement of this program

External Coverage

The collaboration was publicly announced by Onco-Innovations and has been reported by multiple financial and business news outlets.

Read the official announcement from Onco-Innovations →

View coverage on Yahoo Finance →

Posted on by

Nanosoft Polymers’s functional lipid has been used to develop targeted liposomes for precise tumor diagnosis and therapy.

Aminopeptidase N (APN/CD13) is closely related to the growth of cancers and is suggested as a suitable target for anti-cancer therapy.  Recently, a research group used the “one-bead-one-compound” (OBOC) approach on a microarray device to scren out a novel affinity peptide LN (YEVGHRC). It was found that LN could specifically recognize and bind to APN; Moreover, LN-functionalized liposomes (LN-LS) could achieve efficient nano-encapsulated drug delivery under APN-overexpressing tumor conditions in vitro and in vivo,   providing a new strategy for APN-positive tumor diagnosis and therapy.  2017 Feb 28;5(3):417-421.

Posted on by

Nanosoft Polymers’s functional lipid has been used to develop HER2 targeted liposomes for cancer therapy

HER2 is a biomarker of human breast cancer has become an important validated therapeutic target in breast cancer. Recently, a research published in Theranostics using OBOC to screen  a library of novel HER2 targeting peptides. These targeting peptides were conjugated to DSPE-PEG-Maleimide (Nanosoft Polymers) to develop HER2 targeted liposomes for doxorubicin delivery to improve the cancer therapy and diagnosis.  Geng L. et al. HER2 Targeting Peptides Screening and Applications in Tumor Imaging and Drug Delivery. Theranostics. 2016: 6(8): 1261-1273.